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Substantial efforts have been made to
develop in vitro and short-term tests for
predicting mutagenesis and possible car-
cinogenesis. Such tests already play an
important part in the development ofnew
chemicals, though early hopes that they
could replace rodent bioassays have not
been realized. Ashby and Morrod (1) sug-
gested using a more imaginative approach
to predict potential human carcinogens,
including the use ofstandard genetic toxi-
city tests, possible use of the new rodent
transgenic mutation assays, and an overall
emphasis on mechanistic studies. The lat-
ter are of particular importance in assess-
ing human risk from nongenotoxic rodent
carcinogens. Genetic variation in the
response ofrodents to toxic chemicals may
have important implications for such a
scheme for two reasons. First, all current
rodent bioassays use a single strain ofmice
and/or rats. The extensive Carcinogenic
Potency Database on over 450 chemicals,
which has been built up over more than
20 years by the National Toxicology
Program carcinogenesis bioassay (NTP-
CB), mostly using F344 rats and B6C3F1
hybrid mice (2), provides the main tool
for validating alternatives to the rodent
bioassay. At the First World Congress on
Animal Testing and Alternatives, held in
Baltimore, Maryland, in November 1993,
the NTP database was frequently
described as the "gold standard" against
which all alternatives should be tested. Yet
Ashby and Purchase (3) found that among
100 chemicals judged to be rodent noncar-
cinogens, 25 were mutagenic in
Salmonella, and among 162 chemicals in
which there was either clear or some evi-
dence of rodent carcinogenicity, only 91
were mutagenic in Salmonella. Such a dis-
appointing correlation between the rodent
bioassay and the short-term tests may be
due to the inadequacy of the short-term
test, but it may also be due to a fault of
the rodent bioassay. If some carcinogens
have been missed because F344 rats and
B6C3F1 mice happen to be resistant to
some chemical carcinogens, then the value
of the in vitro tests may be questioned, as
theywill appear to be too sensitive.
Second, where strains do differ in
response, studies of the reasons for such
differences may provide a useful additional
tool for mechanistic studies. So far, this
approach has rarely been used by toxicolo-
gists.
Problems with Current Testing
Method
The current NTP carcinogenesis bioassay
involves administering the test compound
to B6C3F1 hybrid mice and F344 inbred
rats for a substantial proportion of their
natural life span. However, many forms of
human cancer depend both on an environ-
mental insult such as cigarette smoke and
on genetic susceptibility. Thus, although
smoking is widely regarded as being one of
the most important causes of human can-
cer, most people who smoke do not devel-
op lung cancer. Part ofthe individual vari-
ation is due to genetic factors (4,5). In lab-
oratory rats and mice, such genetic varia-
tion is most clearly seen as strain differ-
ences in response to carcinogens and other
toxic chemicals. For example, Shellabarger
et al. (6) found that when diethylstilbestrol
(DES) was administered to Sprague-
Dawley (SD) rats, even spontaneous mam-
mary tumors were almost eliminated.
Thus, when tested with SD rats, DES
would be judged a noncarcinogen.
However, in the same study, more than
70% of ACI rats developed mammary
tumors when treated with DES, compared
with less than 1% in the controls, so when
tested in a different strain, DES would be
considered a powerful carcinogen. Thus,
whether or not a chemical is classified as a
carcinogen may depend entirely on the
chance ofwhether the strain chosen for the
bioassay happens to be genetically suscepti-
ble or resistant to the chemical. The scien-
tific method should reduce and quantify
the effects of chance on the experimental
outcome. If the outcome of any particular
NTP-CB depends largely on unquantified
chance, then it can hardly be called a scien-
tific procedure.
Mouse and/or rat strain differences
have been reported in response to a wide
range of chemicals, including carcinogens
such as 9,10-dimethyl-1,2-benzanthracene
(DMBA), urethane, 3-methylcholanthrene,
1,2-dimethylhydrazine, 4-nitroquinoline
N-oxide, 3,4-benzpyrene (7,8), teratogens
such as cortisone (9) and 2,4,5-trichloro-
phenoxyacetic acid (10), and acute toxins.
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For example, Pohjanvirta et al. (11) found
that the LD50 of TCDD varied by two
orders ofmagnitude between two strains of
rats. A strain that is highly sensitive to the
acute toxic effects of a chemical may have
such a low maximum tolerated dose that
no extra tumors are observed during the
normal carcinogenesis screening period.
Table 1 gives some additional examples of
strain differences in response to carcino-
gens. For example, Lijinsky et al. (12)
applied methylnitrosourea to the shaved
skin of groups of 20 mice from 4 strains.
In strain CD-1 only three mice developed
tumors (15%), whereas all the BALB/c
mice developed them. The statistical impli-
cations ofthese results are discussed later.
In the past such strain differences have
been of great importance in stimulating
research into toxic mechanisms. Much of
the work on cytochrome P450 and the Ah
locus followed observations oflarge mouse-
strain differences in response to carcino-
gens such as 3-methylcholanthrene associ-
ated with the inducibility of arylhydrocar-
bon hydroxylase (13). Similarly, over a
period ofsome years, Drinkwater and col-
leagues (14) have been studying the mech-
anisms of hepatocarcinogenesis in mice,
based on the finding that strain C3H is
susceptible and C57BL/6 is resistant to the
induction of liver tumors by a variety of
carcinogens. Much ofthis difference seems
to be due to a single genetic locus designat-
ed Hcs (for hepatocarcinogen sensitive),
which may affect the proliferative rate of
both normal and preneoplastic hepatocytes
(15). These two examples clearly show that
strain differences can be used in the study
of toxic mechanisms, even though a full
understanding usually requires further
extensive research.
In view of such large strain differences
in response to known powerful carcino-
gens, the wisdom ofusing a single strain of
mice and/or rats is questionable.
Weindruch and Masoro (16) expressed
grave reservations about the overuse of
F344 rats in gerontological research, point-
ing out that the extent to which results
obtained with a single strain can be gener-
alized is unknown. They went on to sug-
gest that "It seems appropriate to encour-
age the development of several genotypes
in ageing research.... (16: p. 88). Yet
carcinogenesis screening, which is ofmuch
more immediate importance to human
health, continues to be done using a single
strain ofmice and rats, and those involved
with the NTP-CB appear to be making no
effort to devise a better strategy.
Optimum Deployment ofResources
In the current NTP-CB the test chemical
is administered to groups of 50 mice or
rats of each sex. Each group consists of a
Table 1. Some examples of strain differences in response to carcinogens
Carcinogen
Methylnitrosourea
7,12-dimethylbenz[al-
anthracene
3,2'-dimethyl-4-
aminobiphenyl
N-methyl-N'-nitro-
N-nitrosoguanidine
N-methyl-N'-nitro-
N-nitrosoguanidine
Diethylnitrosamine
Iron plus
hexachlorobenzene
Comment
Applied to shaved skin of groups of20 female mice
treated at8-weeks old. Tumors were 40% in Swiss
(10% in Swiss controls), 70% in SENCAR (5% in
SENCAR controls), 15% in CD-1 (0% in CD-1 controls),
and 100% in BALB/c (0% in BALB/c controls).
Gastric intubation in 10 rat strains. No mammary
tumors seen in the COP strain, 1.2tumors/rat in the
F344 strain, and 5.0tumors/rat in the OM strain.
50 mg/kg given subcutaneously for 10weeks. Tumors
of prostate seen in 48% of F344, 41% ofACI, 13% of
LEW, 7% ofCD, and 0% ofWistar rats.
Single oral dose given to 5-day-old or 28-day-old
ACI orWF strain rats. 58% tumors in glandular stomach
seen in ACI rats, none in WF. Forestomach tumors
seen in both strains. Lung tumors in 64% ofWF rats
treated at 5 days, but none in ACI rats.
100 pg/ml in drinking waterfor30 weeks. Adenocar-
cinomas of glandular stomach in 60% of SD, 67% of
WKY, 53% of LEW, 23% ofWistar and 6% of F344 rats
atweek 50.
Single intraperitoneal dose at8 weeks of age. 50%
heptaocellular carcinomas seen in strain R16 rats but
only3% in strain ACP rats.
90% hepatocellular carcinoma seen in C57BL/10 mice,
but none in DBA/2, though the experiment in the latter
strain had to be terminated after 10 months due to
excessive mortality.
control, a top dose level given the maxi-
mum tolerated dose (MTD; defined as the
highest dose ofthe test agent given during
the chronic study that does not alter the
animals' normal longevity from effects
other than carcinogenicity) and two more
groups which usually receive 50% and
25% of the MTD, though this protocol
has varied slightly (17). Each assay uses
400 animals of each species and costs
approximately $1-2 million or more,
though this can vary widely depending on
dosing methods and other factors. It would
be unacceptable for an "improved" assay to
use any more animals or to cost substan-
tially more. Thus, if it is accepted that
there may be large strain differences in
response, the question is, what arrange-
ment ofgenotypes within each dose group
of 50 animals would be optimum for
detecting a carcinogen, given that the
response may be under genetic control?
ThreeAlternatives
Outbred stocks. "Outbred stocks" of labo-
ratory mice and rats are closed colonies
which are usually propagated by some
form of random or haphazard mating, or
sometimes by a breeding system that
avoids the mating of close relatives. The
effect is a colony ofanimals that is reason-
ably uniform in its characteristics, though
each individual is genetically distinct.
Outbred stocks have sometimes been com-
pared with the genetically variable human
population, but this is misleading because
Reference
(12)
(54)
(55)
(56)
(45)
(57)
(48)
often the amount of genetic variation is
substantially less than that found in
humans. Outbred stocks are often known
by generic names such as "Wistar" and
"Sprague-Dawley" rats and "Swiss" mice,
or alternatively by a more specific code
name given by the breeder. However, as a
result of genetic assortment, inbreeding,
and selection, different colonies of Wistar
and Sprague-Dawley rats and Swiss mice
will be genetically different from one
another.
Many toxicologists have favored the
use of genetically variable outbred stocks
because they contain more than one geno-
type (18). For example, Arcos et al. (19)
considered that it is more correct to test on
a random-bred stock on the grounds that it
is more likely that at least a few individuals
will respond to the administration of an
active agent in a group which is genetically
heterogeneous. There are a number ofseri-
ous disadvantages in using outbred animals
for carcinogenesis screening, but this does
not invalidate the desirability of using
more than one genotype.
One problem is that the actual degree
of genetic variability depends on the past
history of the strain and in many cases is
quite limited. For example, Festing (20)
used DNA fingerprinting to study genetic
variation among 10 inbred strains and 6
outbred stocks ofrats, including 3 colonies
of Wistar, 2 of Sprague-Dawley and 1
Hooded Lister stock. Genetic variation was
assessed by the degree of band sharing
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between any two individuals (21). The
members ofan inbred strain are like identi-
cal twins and, as expected, there was little
variation within inbred strains (approxi-
mately 100% band sharing), except when
colonies had been kept separately for sever-
al years or there was genetic contamina-
tion. The degree ofband sharing across the
10 different inbred strains was 34 ± 15%,
which is about what would be expected
among humans picked at random. In con-
trast, within the six outbred stocks the
band sharing ranged from 84 to 95 ± 5%.
This implies that within these stocks there
was a high degree ofgenetic uniformity. In
all samples there were pairs ofrats that had
identical fingerprints (Fig. 1), a result that
would be virtually impossible in a small
sample of humans (assuming identical
twins were excluded). Thus, the level of
genetic variabilitywithin outbred rat stocks
falls far short ofthat found in human pop-
ulations, whereas differences between dif-
ferent inbred strains seem to be ofthe same
order of magnitude as differences between
individual humans. Few studies have been
conducted on genetic variability in outbred
mouse populations. The most detailed
study was that of Rice and O'Brien (22),
who found that there was still substantial
genetic variation in three outbred mouse
colonies, even though they had been main-
tained as closed colonies for several years.
Whether these conflicting findings reflect a
true species difference or are a reflection of
the different methods ofquantifying genet-
ic variation remains to be determined. It is
possible that rat colonies have, in the past,
been maintained with fewer breeding pairs,
leading to closer inbreeding, simply
because rats are larger than mice and take
up more breeding space.
In any case, it is technically simple to
produce a genetically variable stock by
crossing several strains. However, a stock
with uncontrolled genetic variation pro-
Figure 1. DNA fingerprint of seven outbred hood-
ed Lister rats. Note that 5 of the rats have about
14 bands that can be resolved, and all bands are
identical. Two other rats have a slightly different
pattern. The chance of two human DNA finger-
prints matching in this way is very low, provided
identical twins can be excluded.
duced in this way is not ideal because it is
impossible to ensure that treated and con-
trol groups are genetically identical at the
start ofthe study. All carcinogenesis bioas-
says are done against a background of
spontaneous tumors, many of which are
genetically determined. Using an outbred
stock may occasionally result in more
genetically determined spontaneous
tumors occurring in the treated than in the
control groups by chance. These would be
mistaken for chemically induced tumors,
leading to a false positive result (i.e., the
chemical is classified as a carcinogen when
it is not one). Also, unless the pedigree of
each individual animal is known, which is
usually impractical, it is impossible to
know whether any variation in response to
the test chemical is due to genetic factors.
There are several other disadvantages in
using outbred stocks. Over a period of a
few years the genetic composition of
colonies is likely to change due to selection
and genetic drift, so the characteristics of
the stock will change. This can be mini-
mized by maintaining large colonies with
breeding schemes designed to minimize
inbreeding and genetic drift, but such
schemes can be difficult to administer and
can be expensive. Genetic quality control
of outbred stocks, aimed at ensuring that
they have not become mixed with other
stocks, is difficult. Consequently, few out-
bred colonies are monitored. At present
there are not even any genetic markers that
will distinguish between Wistar and
Sprague-Dawley rats. These have to be
taken on trust from the supplier.
Isogenic (inbredandF1 hybrid) strains.
Inbred strains have been developed by many
generations ofbrother x sister mating with
all individuals tracing back to a common
ancestral breeding pair in the 20th or a sub-
sequent generation (in order to eliminate
the many parallel branches that could devel-
op). The resulting inbred strain is almost
like an immortal done ofgenetically identi-
cal individuals which are also homozygous
atvirtually all genetic loci. Geneticvariabili-
tywithin the strain is eliminated, leading to
greater phenotypic uniformity, so statistical
precision is increased. The strain stays
genetically constant for long periods oftime
so that background data collected on such
strains remains valid for longer periods, pro-
vided that the environmental conditions
remain constant. Genetic quality control
methods to ensure that the correct strain is
being used are much easier to apply than in
outbred stocks. Each inbred strain is desig-
nated by a code consisting ofuppercase let-
ters, and sometimes numbers, such as
C57BL and F344, following rules devel-
oped by the Committee on Genetic
Nomendature ofthe Mouse (23) and a simi-
larcommittee forthe rat (24).
F hybrids are the first generation cross
between two inbred strains. Like inbred
strains, they are isogenic (i.e., all individu-
als are genetically identical), and have all of
the useful properties of inbred strains
except that they are not homozygous at all
genetic loci, and they tend to be more vig-
orous than inbred strains.
The NTP-CB uses two isogenic strains
for carcinogenesis bioassays: the B6C3F1
hybrid mouse and the F344 inbred rat
strain. However, the use of a single iso-
genic strain is rather like using a clone of
genetically identical humans in a clinical
trial. Given that humans vary genetically,
no single individual could represent the
human race. Ifthe isogenic strain happens
to be relatively resistant to the carcinogenic
effect and/or highly sensitive to acute toxi-
city by the chemical, leading to a low
MTD, then no increase in tumor inci-
dence may be seen by the end ofthe bioas-
say, giving a false-negative result (i.e., a
rodent carcinogen is classified as a noncar-
cinogen).
Multistrain experiments. A third possi-
bility, which appears to offer many advan-
tages (25,26), is to use several strains, but
without increasing the total size of the
experiment. In effect this is a bit like creat-
ing a "synthetic" outbred stock with many
of the advantages of an outbred stock in
terms ofgenetic variability, but with few of
the disadvantages. The strains would be
mixed in defined groups, without losing
the identity of each individual. For exam-
ple, instead ofusing 50 animals per group,
all ofthe same isogenic strain, it would be
possible to use 48 animals per group, but
with a mixture of, say, 12 animals ofeach
offour different isogenic strains individual-
ly randomized to each treatment group.
This would immediately quadruple the
number of genotypes and reduce the
chance that all ofthe animals were resistant
to the test compound. The introduced
between-strain variation would usually be
much greater than the within-strain varia-
tion found in outbred stocks (27: p. 241).
This design would avoid one of the main
problems associated with the use of out-
bred stocks, as the treated and control
groups would always be genetically identi-
cal at the start of the experiment, thereby
reducing the chance of false-positive
results. This scheme would have all the
advantages of using isogenic strains, such
as long-term genetic stability and pheno-
typic uniformity, but without the major
disadvantage of using animals of only a
single genotype. It should not significantly
increase the cost, as the total size of the
experiment would be the same, and theo-
retical studies show that statistically it
would normally be more powerful than
using a single isogenic strain (28). It would
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also show whether the response is highly
polymorphic or is uniform across strains.
Tennant (29) has suggested that com-
pounds that cause cancer in animals of
many genotypes are more likely to be
human carcinogens than those which only
cause cancer in limited range ofgenotypes.
The multistrain bioassay should give a
much better estimate of the extent of
genetic variation in response.
There may be other substantial advan-
tages. For example, strains that are relative-
ly susceptible to a carcinogen usually have
a shorter latency to develop tumors. In
some cases, it may be possible to terminate
a study earlier, thereby saving time and
money. For example, Smith and colleagues
at the Medical Research Council Toxi-
cology Unit in Leicester, UK, have found
that the latency to develop liver carcinoma
after dietary administration oftamoxifen (a
known rat liver carcinogen) was approxi-
mately 20 months in F344 rats (the strain
used in the NTP-CB), whereas there was a
100% incidence in LEW and Wistar rats
after only about 11 months. A saving of9
months in obtaining a positive result may
be of considerable interest both to the
NTP-CB and to the pharmaceutical indus-
try.
More than 25 years ago, Heston clearly
stated the case against outbred stocks and
for using more than one isogenic strain:
Yet the question is sometimes asked, why
not use genetically heterogeneous stock mice
so the results will be more applicable to the
genetically heterogeneous human population?
The answer is that we are not trying to set up
a model with mice exactly comparable with
humans. This would be impossible because
mice and men are different animals. What we
are trying to do is to establish certain facts
with experimental animals and this can be
done, or done more easily, when the genetic
factors are controlled. Once the facts are
established we then, with much common
sense, see how the facts can be related to man.
When genetic variability is desired this
can be obtained in the highest degree by
using animals of a number of inbred strains.
This variation between strains is usually
much greater than is found in animals of a
non-inbred stock which actually may be
rather uniform although more variable than
an inbred strain. (30: p. 5)
These words are still true more than a
quarter of a century after they were first
published.
AnAdditional Method for Studying
ToxicMechanisms
A potentially important benefit ofthe mul-
tistrain carcinogenesis assay is that it may
provide an additional wayofstudying toxic
mechanisms. In the past, animals used in
the rodent bioassay were virtually regarded
as a "black box." Ifthey developed tumors,
then the test substance was regarded as a
(human) carcinogen, and appropriate safe-
ty precautions were specified. If no extra
tumors were observed, the substance was
regarded as a noncarcinogen. Recently,
however, much more emphasis has been
placed on understanding the underlying
mechanisms (1). The data are interpreted
in the light of detailed pharmacological
and toxicological studies aimed at a much
fuller understanding of the fate of the
chemical in the body. It is even widely
accepted that some rodent carcinogens,
such as certain hydrocarbons causing kid-
ney tumors in male rats, associated with
the male rat urinary protein a2u globulin,
may not be carcinogenic in humans. The
NBR strain of rats, which has a genetic
defect preventing it from producing a2u
globulin, is resistant to the induction of
these tumors (31). This is a simple exam-
ple ofthe way strain differences in sensitiv-
ity may be used to explore mechanisms.
The use of strain differences to study
mechanisms has been applied successfully
as a research tool, but it has rarely been
used in screening, possibly because it is
rare to use more than one strain. The stud-
ies ofliver carcinogenesis caused by tamox-
ifen, mentioned above, illustrate the way in
which strain differences can provide addi-
tional information that may be ofvalue in
understanding mechanisms.
Tamoxifen is used to treat women with
breast cancer and is now undergoing clini-
cal trials as a chemopreventive agent for
women at high risk of developing breast
cancer. However, it is known to cause liver
carcinoma in rats. Thus, it is important to
gain a clear understanding of mode of
action and whether this mechanism is like-
ly to be operative in women.
Tamoxifen was administered in the diet
(420 ppm, corresponding to approximately
40-50 mg/kg/day in F344 rats) to F344,
Wistar, and LEW strain rats (32). Fifteen
treated and control rats (5 per strain) were
sacrificed at 3 and 6 months for detailed
pathological and biochemical investigation,
and the rest (10 rats per strain in treated and
control groups) were kept until they showed
evidence of tumors or loss ofcondition. By
10 months, all the tamoxifen-treated Wistar
and LEW rats had developed liver carcino-
ma, but none ofthe F344 rats developed evi-
dence oftumors until at least 20 months of
treatment, and these tumors appeared to be
less aggressive, involving a smaller propor-
tion ofthe liver. Thus, the F344 rats had an
increase in tumor latency of about 10
months. Had tamoxifen been a weaker car-
cinogen, or had F344 had a slightly longer
latency, tamoxifen may have been dassified
as noncarcinogenic inthis strain.
The longer latency to develop tumors
in F344 rats (32) was associated with a
reduced tamoxifen intake, increased blood
levels, lack of development of multidrug
resistance (33), a delayed build-up ofDNA
adducts, and a reduction in cell division in
the liver when compared with the other
two strains. At present, it is not clear
which, if any, of these differences are of
critical importance. Although the use of
more than one strain has not solved the
problem of the exact mode of action of
tamoxifen in causing liver cancer in rats, it
has provided a framework for further
investigation, and it did not increase the
total size ofthe experiment: 15-20 control
and treated rats at each time point would
have been used in any case. It also shows
that there is genetic variation in the
response to tamoxifen in rats which was
not apparent when a single strain was used.
If such variation is present in rats, then it
may also be present in humans. With cur-
rent rapid advances in molecular genetics,
it may be possible to identify some of the
genes involved, and their human homo-
logues could be identified. Although this
would be a major research project, the
identification ofgenes controlling suscepti-
bility to carcinogens in laboratory animals
and the identification of human homo-
logues appears to be a promising long-term
research goal.
Tamoxifen is not known to cause liver
cancer in mice. However, this may be
because most mice die by about a year of
treatment due to overgrowth of spinal
bone causing kyphosis. In a multistrain
trial, all C57BL/6 and DBA/2 mice died in
this way before they were a year old.
However, B6C3F1 hybrid mice were much
more resistant, and continue to survive
tamoxifen treatment beyond 22 months of
age. Whether they will develop tumors is
not yet known, but at least it should prove
to be possible to treat this strain of mice
for a large proportion of their normal life
span. In this case, the multistrain experi-
ment is better because ofthe discovery ofa
strain that is resistant to the noncarcino-
genic toxic effects ofthe compound, mak-
ing it possible to carry out a reasonable car-
cinogenesis bioassay.
More research is needed to develop
these methods. However, with recent rapid
advances in genetics, the use of strain dif-
ferences to study mechanisms appears to be
ripe forexploitation.
Examples ofMultistrain Studies
The theory of multistrain toxicity screen-
ing has been discussed in a number ofpub-
lications (18,25,30,34-36) and at several
conferences, and a number ofsuch studies
have been done. For example, Heston et al.
(37 studied the effects of the antifertility
drug Enovid in five mouse strains and
found no evidence that it was carcinogenic.
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More recently, Wolffet al. (38) studied the
response of four Fl hybrids to 2-acetyl-
aminofluorine using a design of the sort
proposed here. They found only small dif-
ferences between the hybrids, possibly
because Fl hybrids tend to be intermediate
in phenotype. They confirmed theoretical
studies that the statistical precision was
similar using 48 B6C3F1 mice or 12 mice
of each of the 4 hybrids, as would be
expected when there are no important
strain differences. Kalter (9) used several
strains in a study of susceptibility to the
induction of cleft palate by cortisone
acetate and found that C57BL/6 was 9- to
34-fold more resistant than strain A/J.
Holson et al. (10) used four inbred
strains and one outbred stock in a multi-
replicated dose-response study of the ter-
atogenic effects of 2,4,5-trichlorophenoxy-
acetic acid (2,4,5-T). They found that
C3H/He and BALB/c mice were 3.5- to 5-
fold more resistant to 2,4,5-T than the A/J
strain, though the dose-response lines
among all strains were parallel, and they
concluded that similar mechanisms were
involved with all strains. They did not
think that the strain differences were great
enough to outweigh the practical difficul-
ties of using several strains in a teratology
study, but it could not have been foreseen
that a teratogenic effect would be observed
in all strains. Moreover, following Tennant
(29), the fact that a teratogenic effect was
observed in all genotypes would suggest
that 2,4,5-T is more likely to be a human
teratogen than if the effect was only
observed in a single strain.
Consequences ofthe Multistrain
Experiment
Although a reasoned scientific discussion
of possible disadvantages of multistrain
experiments has not been published, a
number of potential objections have been
discussed at scientific conferences.
More chemicals would bejudged to be
carcinogenic. If the rodent carcinogenesis
bioassay is improved, more chemicals will
be judged to be rodent carcinogens. There
is real concern that too many chemicals are
already classified as rodent, and therefore
presumed human, carcinogens (3,39). This
is sometimes used as an argument against
improving current testing methods. While
this is a genuine worry that needs to be
taken into account in introducing better
methods, it should not be used as an
excuse for inaction. In the real world,
humans are continually being exposed to
natural and man-made carcinogens. In
many cases this is of little significance
because the dose levels are very low and/or
the carcinogens are relatively weak.
Eventually, the carcinogenic potential of a
xenobiotic may have to be assessed on a
quantitative or semi-quantitative scale of
potency rather than the present dichoto-
mous scale of"carcinogen/noncarcinogen."
In practice, this already happens with
many compounds that are known rodent
carcinogens still being widely distributed,
with suitable precautions to ensure reason-
able safety standards.
It should also be recognized that risk
assessment is a two-step process. The car-
cinogenic potency or hazard ofa chemical
must first be established in animals that
have been chosen because observations in
these animals are believed to be relevant to
humans. The animal data are then used to
assess human risk, taking into account all
available biological information (30),
which may even suggest that the mecha-
nism by which the chemical causes tumors
in rodents is not relevant to humans.
However, ifthe animal data are inaccurate,
they may well lead to contradictory con-
clusions. For example, the in vitro and
short-term tests may predict that the
chemical will be a genotoxic carcinogen. If
the rodent bioassay then gives no evidence
ofcarcinogenicity, this may be because the
rodent bioassay is inaccurate, or there may
be real problems with the short-term tests
which need to be explored. Unfortunately,
the rodent bioassay is so expensive that it is
unlikely to be repeated, and there is a nat-
ural tendency to assume that the animal
rather than the in vitro test provides the
definitive result.
Practical difJiculties. Potential practical
problems arise from the increased complexi-
ty, the danger ofstrains becoming confused,
and the extra cost of multistrain tests.
However, strains could be chosen that differ
in coat color, or some other easily detected
genetic marker, and the animals can be
physically marked, so the chance ofgetting
them confused would be minimal. There
would be no necessity to start the assay on
all the strains simultaneously so, assuming
four strains were to be used, the experiment
could be divided up into four smaller exper-
iments, which would help to spread the
workload. Objections on the grounds ofthe
cost are sometimes raised. The cost of the
NTP-CB is largely due to the cost ofmain-
taining the animals and the subsequent
costs associated with the pathological stud-
ies. These costs are largely dependent on the
total number of animals, which would not
be altered. However, metabolic studies
would need to be done on all strains, which
may increase the cost, though again in most
cases the total number of animals should
not need to be increased. In the end, any
extra costs must be equated with the advan-
tages ofsuch adesign.
Scientific questions. Scientific questions
that need further discussion include the
number of and choice of strains and the
problem ofstrain differences in the MTD.
The optimum number of strains will
only be determined in the light ofpractical
experience on the real extent of strain dif-
ferences. Two strains would be better than
one, but more strains would be needed to
explore relationships between variables
such as rate of metabolism and sensitivity.
Four strains might be a useful starting
point, with numbers modified by later
experience. Rao et al. (40: p. 390) favored
the use of an Fl hybrid on the grounds
that "... it has a major advantage in that
the level ofheterozygosity may more close-
ly resemble that ofthe noninbred individ-
ual of the species." However, there is no
evidence that the level of heterozygosity
has any bearing on response to carcino-
gens. Fl hybrids tend to be intermediate in
response, which may be an advantage if a
single strain is used, but if several strains
are to be used, and the aim is to get as wide
a range of different genotypes/phenotypes
as possible, then they should not all be F
hybrids.
Theoretically, different strains might be
chosen for each study on the basis of
known susceptibility to compounds chemi-
cally related to the compound being tested.
This approach was used by Heston et al.
(37) in their study of Enovid. They gave
detailed reasons for choosing each of the
five strains. Another alternative, suggested
byWolffet al. (38), would be to use a sub-
chronic assay to pick the most appropriate
strains. No correlation has been established
between acute toxicity and carcinogenesis,
but whether or not there is some associa-
tion between the incidence of preneoplas-
tic foci and susceptibility in different
strains, as found in studies with tamoxifen,
remains to be evaluated.
A good case could be made for using a
fixed panel (as is current practice) of, say,
four rat and mouse strains chosen because
they have a long life span, differ genetical-
ly, and have no serious defects. A suitable
panel of mouse strains might be B6C3F1
(for continuity), C57BL/6, and DBA/2,
two strains favored by the National
Institute on Aging (41), and either
B6D2F1 or BALB/c. Suitable rat strains
could include F344 (for continuity), BN,
F344BNF1 [all three ofwhich are favored
by the NIA (41)] and possibly WAG.
None of these strains (including the
B6C3F1 mice and F344 rats) are entirely
free ofdisadvantages, and other candidates
could also be considered. Should genetical-
ly engineered strains with, for example,
human drug-metabolizing enzymes
become available in the future it would be
possible to substitute them for one of the
strains. In this way a rnultistrain design
could evolve as new animal models become
available, while retaining ties with the past
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in the form of the F344 rat and the
B6C3F1 mouse strains.
Another problem is that the MTD
would probably be strain dependent.
Multistrain subchronic studies would be
needed to determine the MTD for each
strain and, either each strain would have to
have a different dose level, or they could all
be given the dose of the most sensitive
strain. The latter approach would probably
be quite acceptable unless the MTDs differ
markedly between the strains. In effect,
this is what happens in the pharmaceutical
industry, which largely uses genetically
variable outbred stock. In this case the
MTD would tend to be biased in favor of
the most sensitive individuals. Further
research is needed on this topic.
Statistical validity and theproblem of
group size. Toxicologists frequently express
unease about the statistical validity of a
multistrain design. Part of the problem
seems to be differences in perception ofthe
size ofthe groups that are to be compared.
Many toxicologists immediately look
for a group ofanimals that are identical in
every respect except for the applied treat-
ment and regard this as the basic unit for
comparing treatments. Thus, with a single
isogenic strain and 48 animals per group,
they would be comparing 48 control ani-
mals with 48 animals in one of the treat-
ment groups. However, with a 4-strain
experiment they assume that they would
only be comparing 12 control animals of
each strain with 12 animals in the treated
group, and this would have to be done
four times. Inevitably, they consider group
sizes of 12 animals as being too small, so
they reject the multistrain experiment on
the grounds that it lacks statistical power.
This is a misunderstanding ofthe concept
of what constitutes a "group." The prob-
lem can be clarified by considering the fol-
lowing: Assume for simplicity that a
screening experiment involves only a treat-
ed and a control group, with 48 animals in
each. These groups can be set up in various
ways:
. Single isogenic strain: If a single isogenic
strain is used, with 48 animals per group,
then it is clear that the group size is 48
animals.
. Single nonisogenic strain: What is the
group size if a single nonisogenic (out-
bred) stock is used? In an outbred stock
all individual animals are genetically dif-
ferent. Does this mean that ifan outbred
stock is used there are 96 groups of one
animal? Clearly not. Everyone who uses
outbred animals still considers that they
have two groups of48 animals, so clearly
a "group" does not have to be genetically
homogeneous.
. Single nonisogenic strain, animals typed
at a marker locus: Suppose next that
somebody types the outbred animals for
a particular genetic marker after an exper-
iment is concluded and finds that half
the animals ofeach group are type A and
the other halfare type B. There are now
two treated and two control groups of24
animals instead of two groups of 48.
Would this experiment now be less pow-
erful just because somebody had typed
the animals genetically? Could it be sta-
tistically more powerful not to type the
animals? Can ignorance be more statisti-
cally powerful than knowledge? Or can it
be argued that it makes little difference
whether the animals have been genetical-
ly typed, the comparison between the
treated and control groups is still based
on 48 animals per group? A little reflec-
tion suggests that the latter argument is
valid, but that if the animals have been
typed, then this adds some information
which may be useful. The basic compari-
son would still be between a treated and a
control group of48 animals, but ifit was
found that tumors were only observed in
treated animals of type A, then this
would provide additional information
that was not available before the animals
were typed. Clearly, in some circum-
stances it is biologically more powerful,
and statistically no less powerful to know
the genotype ofthe animals.
Multistrain, "blind" experiment with 4
strains done: Suppose next that a multi-
strain screen is set up with 48 animals in
the treated and control groups, consisting
of 4 strains with 12 animals per strain,
but that the experimenter is "blind" with
respect to strain of animal. Suppose the
experimenter observes 0/48 tumors in the
controls and 12/48 in the treated group
(or alternatively 0/48 in both groups). Is
this experiment invalid as a carcinogene-
sis screen? The answer is no. There does
not seem to be any reason why the treat-
ed and control groups should not be
compared in this way. It has been estab-
lished above with nonisogenic stocks that
the groups being compared do not need
to be genetically isogenic, and given that
the experimenter is blind with respect to
genotype (just like people who use non-
isogenic stocks), he or she has little alter-
native to comparing the 48 treated with
the 48 control animals. This experiment
is really no different from one done with
outbred animals. However, this would
not be a sensible design in practice
because valuable biological information
on the genetic identity ofeach individual
would be wasted.
Multistrain, "unblinded" experiment:
Suppose now that the strain identity in
the above experiment is decoded. Does
this extra information now mean that the
experiment becomes less powerful? Must
the experiment now be analyzed as four
separate experiments, each of which is
too small, or can it still be regarded as 2
groups of48 animals, but with the extra
information on the relationship between
the individual animals? This extra infor-
mation may show, for example, that all
ofthe extra tumors occurred in one par-
ticular strain, or it may show that the
extra tumors were evenly distributed
among all four strains. In either case this
extra information clearly has biological
significance. It would surely be strange if
extra information of this sort made the
experiment less powerful. And, ofcourse,
it does not do so. The experiment can
still be analyzed as a comparison of 2
groups of48, but with additional statisti-
cal tests ofwhether all strains respond in
the same way or whether there is evi-
dence that the response is strain depen-
dent. A full discussion ofthe exact meth-
ods of statistical analysis of such multi-
strain experiments is beyond the scope of
this paper. Felton and Gaylor (28) sug-
gested that one method ofanalysis would
be to use the Mantel-Haenszel test as a
means ofcombining the data from differ-
ent strains. This is discussed briefly
below. However, it should be clear from
the above discussion that the main com-
parison ofinterest is whether the number
of tumors in the 48 treated animals is
greater than in the 48 controls, and the
fact that each group is composed of 4
strains is onlyofsecondary importance.
But the multistrain experiment could
actually be more powerful. On average, the
multistrain experiment should be more
powerfil than the single-strain experiment.
That is one ofthe reasons why it should be
investigated for the NTP-CB assay.
The importance ofsensitivity. The
above arguments show that genetic hetero-
geneity as such does not automatically lead
to reduced statistical power, though strictly
this is only true ifthe genotypes are exactly
balanced between the treated and control
groups. This is possible with a multistrain
experiment but not possible when an out-
bred stock is used, as the genotype ofeach
outbred animal is unknown. Thus, the
genetic heterogeneity of outbred stocks
reduces statistical power, which is the main
justification for the use of isogenic strains
in the NTP-CB.
However, on average, the multistrain
experiment will be more powerful than the
single-strain design. The reason for this is
that the multistrain experiment increases
the chance of including some genetically
sensitive individuals in the test population.
Felton and Gaylor (28) did a detailed
study ofthe statistical power ofmultistrain
compared with single-strain protocols
using the Mantel-Haenszel test. A single-
Volume 103, Number 1, January 1995 49- T . e -ailJIM 3&
- i
strain protocol results in a 2 x 2 table of
tumors/no-tumors in the treated and con-
trol groups for each dose-by-sex subgroup.
A four-strain protocol would result in four
such tables, which need to be combined to
obtain an overall estimate ofstatistical sig-
nificance. The Mantel-Haenszel test (42)
provides a method of combining such
tables. Felton and Gaylor (28) did com-
puter simulations involving 1000 samples
with 48 control and 48 treatment observa-
tions in each case with a range of back-
ground tumor incidences and response
rates. They compared the single-strain pro-
tocol with a 2-strain (24 animals per
strain), a 4-strain (12 animals per strain),
and a 24-strain (2 animals per strain) pro-
tocol using a 1-sided Mantel-Haenszel test
with a significance level of a = 0.05. The
overall conclusions were that
For the case where there is no knowledge of
the sensitivities of available strains, the best
design, in terms ofthe Mantel-Haenszel test,
will generally consist ofusing as many strains
as possible. The risk ofusing such a design is
the possible loss of a small amount of power
where the average increase in the response
rate due to a chemical is small and the power
is small anyway. An advantage of the multi-
strain experiments is the possibility ofa large
gain in power. (28: 409)
The multistrain protocol was slightly
worse than the single-strain one with weak
carcinogens and when all strains were iden-
tical in response (e.g., causing an increase
in tumors of about 5% in all strains).
However, in these circumstances the
chances of any protocol detecting the car-
cinogen would be low. The multistrain
protocol was of about equal power when
the response rate was higher and the strains
did not differ but was substantially more
powerful than the single-strain protocol
when strains differed. Thus, if the exam-
ples given in Table 1 are representative of
the true biological situation, the multi-
strain protocol would normally be much
more powerful than the single-strain one.
The reason for this is that statistical power
does not only depend on sample size. The
sensitivity ofthe test animals is also ofcrit-
ical importance. Ifthe animals are resistant
to the induction of tumors with a particu-
lar agent, as SD rats were to DES when
tested by Shellabarger et al. (6), then the
substance will go undetected as a carcino-
gen however large the sample size.
However, only small numbers of highly
sensitive animals are needed to give a sta-
tistically significant increase in the number
oftumors.
Table 2 shows the sample size that is
needed to give a 90% chance ofdetecting a
difference in tumour incidence between a
treated and control group and declaring it
statistically significant at the 5% level of
probability (one-tailed test) for two levels of
spontaneous tumors in the controls and for
various levels of response in the treated
group [calculated using a program by
Piantadosi (43), using methods somewhat
similar to those described by Snedecor and
Cochran (44), but based on an algorithm
for an exact method for calculation ofbino-
mial confidence limits]. Note that the sam-
ple size needed to detect an effect declines
dramatically as the proportion of affected
animals increases. With a response of 10%
in the treated group against a background
of 1% in controls, the required sample size
is 108 animals in each group, whereas with
a 50% incidence in the treated group the
sample size needed is only 12 animals. This
can be related to the data ofTatematsu et
al. (45), who administered N-methyl-N'-
nitro-N-nitrosoguanidine (MNNG) in the
drinking water (Table 1) and found a 60%
incidence of tumors in SD rats, but only a
6% incidence in F344 rats. Assuming that
these incidences represent the true response
rates in these two strains and that there is a
1% incidence in controls, sample sizes of
229 F344 rats in both control and treated
groups would be required to give a 90%
probability of detecting a 6% incidence of
tumors, whereas a sample size ofonly 9 SD
rats in each group would be needed (calcu-
lations based on 43). Clearly, there would
be a high chance that the NTP-CB assay
using F344 rats would miss MNNG as a
stomach carcinogen, whereas only a few SD
rats would be needed to give a positive
result. Of course, the best result would be
to use just SD rats, but there is no apriori
way ofdeciding which strain is most likely
to be sensitive. In the example given below,
it is the SD strain ofrats that are resistant,
and it is clear that in the absence of any
way of choosing a susceptible strain, it is
best to split up the available material so as
to increase the chances of having a few
highlysensitive animals.
As a further example, consider Shella-
barger et al.'s (6) study ofthe carcinogenic-
ity of DES. They found that Sprague-
Dawley rats failed to develop any excess
tumors when treated with DES. However,
Table 2. Sample sizes needed to compare a treat-
ed and control group
True incidence True incidence
in controls in treated group Sample sizea
0.01 0.1 108
0.01 0.2 43
0.01 0.3 25
0.01 0.5 12
0.1 0.2 217
0.1 0.3 67
0.1 0.5 21
0.1 0.7 10
aln each group, assuming a one-tailed testwith
a = 0.05 and a power(1-,3) of0.9.
about 72% of treated ACI rats developed
tumors compared with less than 1% in
controls (the data have been averaged
across an irradiation treatment).
Assume that on average half of all rat
strains are like ACI and half are like SD,
and one strain with 48 animals per group
is chosen at random for the test. In this
case there will be a 50% chance that a
resistant strain of rats is chosen, and DES
will be declared a noncarcinogen. Suppose
alternatively that the test is set up using 12
rats from each of four strains chosen at
random. The chance that at least one strain
is susceptible will be 1 - (1/2)4 = 93.75%.
If only a single strain is susceptible, and
72% ofrats ofthe susceptible strain devel-
op tumors (between 8 and 9 tumors in the
48 treated animals), this would be judged
to be statistically highly significant, and
DES would be declared to be a carcinogen.
The high strain sensitivity more than com-
pensates for the reduced sample size ofthe
individual strain (though total group sizes
remain the same). So, by increasing the
number of strains from one to four, the
chance of detecting DES as a carcinogen
would be increased from about 50% to
over 90%. Ifeight strains were to be used,
the chance that at least one was susceptible
would be increased to 99.6%, but in this
case ifonly 72% ofthe rats were to devel-
op tumors, only just over four tumors
would be expected, which would not be
statistically significantly different from 0 in
the controls. However, the chance that at
least two strains were susceptible would be
96.5%, and with two susceptible strains
the expected number of tumors would be
over eight, giving a high chance ofa signif-
icant difference. Thus, the use of eight
strains would be marginally more powerful
than the use offours strains, though it may
be impractical to use so many strains.
There is, however, a problem with the
perception of the concept of sample size
with these proposals. Take the case ofthe 4-
strain experiment with 12 animals per
strain. Many people assume that these pro-
posals suggest a reduction in sample size
from 48 animals to 12 animals per group.
This is not the case. The treated and control
groups would still each consist of 48 ani-
mals. It is only the arrangement of geno-
types within that fixed sample size that is
being discussed here. Theoretically, itwould
be possible to design the experiment with
48 strains with one animal ofeach strain in
the treated and control group. Clearly, if
this were perceived to be an experiment
with a group size ofone, itwould be written
offas being impossible to analyze statistical-
ly. In fact, a protocol ofthis sort is entirely
analogous to the use of 48 sets of identical
twins, and nobody would doubt that this
could be analyzedstatistically.
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As noted above, and Felton and Gaylor
(28) concluded that, on average, designs of
this sort are likely to be statistically more
powerful than the present design. Haseman
and Hoel (46) reached somewhat similar
conclusions when comparing the use ofsev-
eral isogenic strains with a pseudo-outbred
stock assumed to be a random mixture of
individuals from the isogenic strains. Their
results suggest that the use of several iso-
genic strains would be better than the use of
a single outbred stock. Lovell (26) found
that such designs would be expected to
detect more carcinogens and should provide
more information on toxicological mecha-
nisms which would be of qualitative value
in assessing human risk, though the multi-
strain design would not improve methodol-
ogy for extrapolating effects to low dose lev-
els, except to the extent that it would avoid
more false negative results. It has been sug-
gested that the same benefits could be
obtained by using another species.
However, it would probably be impossible
to add a third species without increasing the
total number ofanimals used, and therefore
the overall costwould risesubstantially.
A Challenge for the NTP-CB
Part ofthe work ofthe NTB-CB is to con-
duct research into improved methods of
screening for carcinogens. The case for
using more than one strain has been care-
fully argued over a period of several years
(25,34-36), and the statistical implications
have been independently examined and
found to be highly satisfactory. There
appears to be scope for using strain differ-
ences in response as an additional tool for
studying toxic mechanisms, though this
requires more research. The continued use
of a single isogenic strain with its associat-
ed failure to give any estimate ofwhether
or not the same response would be
observed with a different strain is open to
criticism and may be leading to the estab-
lishment ofa database on the carcinogenic-
ity ofchemicals which, far from being the
"gold standard" against which short-term
tests are evaluated, is actually hindering the
development of new short-term tests.
Green noted that
Failure to repeat short-term assays is inexcus-
able; failure to repeat rodent assays is entirely
excusable, but it renders the data unsuitable
as a reference baseline for evaluating other
assays. An assay should not be used as a base-
line, to test the predictivity of other assays,
unless its ability to predict itself is known.
(47: p. 369)
The design of the NTP-CB assay has
remained almost unchanged for more than
20 years, though the science of toxicology
has altered radically during this period,
with increasing emphasis on short-term
tests and on understanding toxic mecha-
nisms. This seems to be an appropriate
time for scientists associated with the NTP-
CB to initiate research into improving the
design, particularly to increase the repeata-
bility ofthe results. One avenue that clearly
needs to be explored is the use ofa multi-
strain design. It is impractical to repeat
individual assays, but at least with a multi-
strain design there should be some estimate
ofthe internal repeatabilty ofthe results. If
the compound causes cancer in all or in
none ofthe strains, it may be a more suit-
able chemical forvalidating short-term tests
than ifit causes cancer in only one organ of
one strain.
Exactly how the other advantages and
disadvantages ofa multistrain design are to
be evaluated needs detailed consideration.
Failure to find strain differences in
response to a few model carcinogens does
not necessarily invalidate the design, as
most potent carcinogens are likely to cause
cancer in all species and strains, and in any
case, the finding that a compound causes
the same result in several strains is valuable
information, as noted above. For general
screening, the design is likely to be most
helpful in detecting apparently weak car-
cinogens where in some strains increased
latency to develop tumors and/or high sen-
sitivity to acute toxicity means that most
animals have not had time to develop
tumors by the end ofthe test period. Table
1 gives an example where iron and hexa-
chlorobenzene gave a high incidence of
hepatocellular carcinoma in C57BUJ10 mice
(48) but none in DBA/2, possibly because
mice of the latter strain died due to acute
toxic effects.
One approach would be to use a multi-
strain assay for substances that have given
equivocal results in a full-scale NTP-CB
rodent assay and which need further inves-
tigation in any case. Responses to non-
genotoxic carcinogens would be ofparticu-
lar interest. Maronpot et al. (49) found a
number of substances that appeared to be
carcinogenic in the strain A lung tumor
assay but were negative in the NTP-CB,
and there are numerous compounds that
are negative in one species and positive in
another (50). Some of these could be
examined on a research scale rather than as
a full rodent bioassay, possibly using quite
small numbers ofanimals ofseveral strains
to see whether one or two strains could be
found that are highly susceptible. It might
be worthwhile doing lifetime studies on
strains that develop high levels of preneo-
plastic foci in short-term studies, or small
scale screening trials might be used to
detect potentially sensitive strains before
doing a full-scale bioassay. All sorts of
strategies could be proposed, once the
principle ofusing more than one strain was
accepted. Ifsusceptible and resistant strains
were found, then biochemical, pharmaco-
logical, and pathological differences
between the strains could be examined to
see ifthey are ofany value in understand-
ing mechanisms and improving available
data for estimating human risk.
The genetic basis could also be exam-
ined in detail using molecular mapping
methods which have only recently become
available (51). Resistant and susceptible
strains can be crossed to produce an F2
hybrid or backcross segregating popula-
tion, individuals ofwhich are treated with
the chemical. Each animal is then typed for
simple-sequence length polymorphic
(SSLP) loci covering all chromosomes. Any
co-segregation between susceptibility and a
particular SSLP marker implies genetic
linkage. In this way, the genes contributing
to strain differences can be mapped and,
eventually, identified. Although this is a
laborious procedure which could only be
done for a few selected compounds, in the
long run it could contribute enormously to
an understanding oftoxic and carcinogenic
mechanisms. Devereaux et al. (52) and
Festing et al. (53) have used these tech-
niques to map the genes controlling sensi-
tivity to the induction of lung tumors in
mice, where strain A/J is highly sensitive
and C57BL/6 is resistant. Susceptibility is
controlled by the sex ofthe mouse and by
loci on chromosomes 6, 9, 17, and 19,
though the locus on chromosome 6 closely
linked to or identical to the K-ras-2 genetic
locus accounted for 60% ofthe total varia-
tion in one ofthe studies (53).
The challenge facing the NTP-CB now
is to demonstrate the extent to which the
assay results obtained with F344 rats and
B6C3F1 mice can be generalized to mice
and rats with other genotypes and can be
used to validate short-term assays. A first
step would be to investigate the extent to
which the NTP-CB results are strain-
dependent.
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